Actively Recruiting
Diphencyprone Plus Immune Checkpoint Inhibition in the Treatment of Cutaneous Metastases
Led by Nicholas Gulati · Updated on 2026-02-10
100
Participants Needed
1
Research Sites
425 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a phase I, open label study employing diphencyprone (DPCP) to characterize gene expression changes of various immune cell and tumor markers in cutaneous metastases treated with topical DPCP twice weekly for 12 weeks in combination with PD-1 or PD-L1 immune checkpoint inhibition (ICI), compared to pre-treatment cutaneous metastases and to describe the adverse events associated with DPCP when administered topically twice weekly for 12 weeks in combination with PD-1 or PD-L1 ICI.
CONDITIONS
Official Title
Diphencyprone Plus Immune Checkpoint Inhibition in the Treatment of Cutaneous Metastases
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Clinically diagnosed cancer with at least three cutaneous metastasis sites that are able to be biopsied.
- Plan to receive FDA-approved PD-1 or PD-L1 immune checkpoint inhibitor therapy as next standard treatment.
- Age 18 years or older.
- Eastern Cooperative Oncology Group (ECOG) performance status between 0 and 2.
- Women of child-bearing potential and men must agree to use adequate contraception before, during, and for 90 days after the study.
- Ability to understand and willingness to sign a written informed consent.
You will not qualify if you...
- Receiving any other investigational agents.
- Receiving combination immune checkpoint inhibition such as PD-1 inhibitor combined with CTLA-4 inhibitor.
- Taking systemic corticosteroids, immunosuppressants, or other medications that may affect study outcomes.
- Having underlying diseases or skin conditions in affected areas that require interfering treatments or impair immune response (e.g., HIV or certain lymph node surgeries).
- History of allergic reactions to compounds similar to diphencyprone or its ointment components.
- Uncontrolled illnesses including active infections, heart failure, unstable angina, arrhythmias, or psychiatric/social conditions limiting study compliance.
- Pregnant or nursing women due to potential risks to infants.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Icahn School of Medicine at Mount Sinai
New York, New York, United States, 10029
Actively Recruiting
Research Team
V
Vicky K Wong, MS, CCRC
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here